EphB4 as a therapeutic target in mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. A search for novel targets and therapeutics is underway, and rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ren, Ferguson, Benjamin D, Zhou, Yue, Naga, Kranthi, Salgia, Ravi, Gill, Parkash S, Krasnoperov, Valery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671960/
https://www.ncbi.nlm.nih.gov/pubmed/23721559
http://dx.doi.org/10.1186/1471-2407-13-269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671960/
https://www.ncbi.nlm.nih.gov/pubmed/23721559
http://dx.doi.org/10.1186/1471-2407-13-269

Ejemplares similares